European School of Oncology
By improving the skills of all health professionals dealing with cancer patients, ESO helps shorten the time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.
ESO’s mission is reflected in its motto “Learning to Care”, which emphasises the importance of the ...
read more ↘
ESO’s mission is reflected in its motto “Learning to Care”, which emphasises the importance of the ...
read more ↘
Lymphoma Course
ESO Lymphoma Course
Chemo-free Therapy for Follicular Lymphoma - Rituximab as Single Agent, Rituximab + Lenalidomide & Other Combinations
FEATURING
Emanuele Zucca
- 162 views
- August 19, 2019
ESO Lymphoma Course
The Mutational Landscape of CLL: Diagnosis, Survival, and Watch and Wait
FEATURING
Davide Rossi
- 331 views
- August 19, 2019
- 2
ESO Lymphoma Course
The Mutational Landscape of CLL: 1st line, Fixed Duration Treatment, TP53 Status, 2nd Line Setting and MRD
FEATURING
Davide Rossi
- 178 views
- August 19, 2019
- 1
ESO Lymphoma Course
R-CHOP Therapy for 61 y/o Male with Stage IIIB bulky DLBCL & Avoiding Radiotherapy if PET-Negative
FEATURING
Alden Moccia
- 13 views
- August 30, 2019
ESO Lymphoma Course
Treatment of 58 y/o Male with Stage IV B Marginal Zone lLymphoma : Transformation of Disease into DLBCL
FEATURING
Alden Moccia
- 45 views
- August 30, 2019
ESO Lymphoma Course
Update on Primary and Secondary CNS Lymphoma: Diagnosis, Treatment Options, Review of Top Trials and Salvage Therapy
FEATURING
Tracy Batchelor
- 63 views
- September 3, 2019
ESO Lymphoma Course
First Line DLBCL: How Many Cycles of RCHOP? Improving Outcomes of CHOP: R-CHOP vs. R-ACVBP vs. DA-EPOCH-R, R-CODOX-M vs. R-IVAC
FEATURING
Andrew Davies
- 243 views
- September 3, 2019
- 1
ESO Lymphoma Course
Current and Future Drug Development in DLBCL: Review of Methodology, Failure History & New Trial Design
FEATURING
Anastasios Stathis
- 29 views
- September 4, 2019
ESO Lymphoma Course
Treatment of 57 y/o Male with B-Lymphoblastic Lymphoma
FEATURING
Bernhard Gerber
- 26 views
- September 5, 2019
ESO Lymphoma Course
The AML Paradigm: From 3+7 for Everybody to Genetic-Driven Personalized Treatment
FEATURING
Martin Fey
- 231 views
- September 5, 2019
- 2
ESO Lymphoma Course
Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP, EP300, HDAC3, TET2, KMT2D, EZH2
FEATURING
Ari Melnick
- 48 views
- September 12, 2019
ESO Lymphoma Course
Biology of Anaplastic Large Cell Lymphomas (ALK+ and ALK-) & Breast Implant‐associated ALCL
FEATURING
Laurence de Leval
- 29 views
- September 12, 2019